Mr Thakore and colleagues (March 2002 JRSM 1 ) conclude that 55% of calls for emergency ambulances did not merit an immediate response. As they acknowledge, the design of the study was not ideal. The initial reason for the request was determined from ambulance crew and accident and emergency (A&E) data after the patient had been seen. This will almost inevitably introduce bias when applying the triage criteria, and the assessment should have been blinded. Also, it is much easier to make such determinations in hindsight, with additional time and clinical information, than when faced with a real call when one has to consider the consequences of the decision reached.
It is surprising that this paper makes no reference to priority-based dispatch systems, such as the Advanced Medical Priority Dispatch System (AMPDS), as these are currently used by most ambulance services in the UK. These systems have been shown to have a low risk of serious under-prioritization of life-threatening episodes 2 . However, work that we have undertaken in Nottingham suggests that they may not be very effective in predicting low-priority 999 calls 3 .
The NHS Executive has stressed the importance of developing telephone prioritization systems that will free ambulance services from having to respond to`patients who dialled 999 but who do not need emergency care' 4 . We believe this may be dif®cult to achieve. Appropriate and effective telephone triage on non-emergency 999 calls requires a greater understanding of the relationship between the initial telephone assessment by ambulance control and the subsequent outcome of the individual call. Without these data we will not be able to ensure that such a system could operate safely and we endorse the authors' views that prospective studies are essential to assess the feasibility of accurately identifying lower priority calls. Fusidic acid monotherapy Dr Biswas and colleagues (February 2002 JRSM 1 ) present two cases of hypocalcaemia arising during fusidic acid therapy. We agree that this could represent a rare sideeffect of fusidic acid. However, we would like to focus on a different aspectÐthat of antimicrobial resistance selection. In both patients fusidic acid was used as monotherapy (for more than one month in case 2, unspeci®ed for case 1). The general view is that fusidic acid should not be used alone because natural mutants with an alteration in the elongation factor G are harboured even at low rates of 10 6 staphylococci 2 . This leads to a rapid spontaneous mutation rate, seen when the organism is grown in increasing concentrations of the drug. Therefore, combination with another antistaphylococcal antibiotic such as¯ucloxacillin or vancomycin will decrease the risk of resistance emergence 1±3 , particularly if the infection is with methicillinresistant Staphylococcus aureus or chronic 4 . The British National Formulary (BNF) recommends`clindamycin alone or¯ucloxacillin+fusidic acid' for the treatment of osteomyelitis 5 . Both patients were taking aspirin during treatment with fusidic acid. There is some evidence that this too could promote the emergence of resistance 6 , and one might consider replacing aspirin with a different antiplatelet agent. In case 1 the patient was concurrently taking aspirin and cipro¯oxacin. According to the BNF such a combination can increase the risk of convulsions even in patients with no previous history 5 and cipro¯oxacin resistance might also increase in the presence of salicylates 7 .
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In conclusion, fusidic acid should be used only in combination with another antistaphylococcal agent, and interactions with even as`benign' a drug as aspirin should be considered.
